Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CKPT

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Checkpoint Therapeutics Inc

CKPT
Current price
4.26 USD 0 USD (0.00%)
Last closed 4.26 USD
ISIN US1628281073
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 370 705 216 USD
Yield for 12 month +93.64 %
1Y
3Y
5Y
10Y
15Y
CKPT
21.11.2021 - 28.11.2021

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts. As of May 30, 2025, Checkpoint Therapeutics, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited. Address: 95 Sawyer Road, Waltham, MA, United States, 02453

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.45 USD

P/E Ratio

Dividend Yield

Financials CKPT

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+41 000 USD

Last Year

+103 000 USD

Current Quarter

Last Quarter

-41 000 USD

Current Year

+41 000 USD

Last Year

-43 463 000 USD

Current Quarter

Last Quarter

+12 936 000 USD
EBITDA
Operating Margin TTM -137 500.00 %
Price to Earnings
Return On Assets TTM -152.73 %
PEG Ratio
Return On Equity TTM -1 869.55 %
Wall Street Target Price 4.45 USD
Revenue TTM 41 000 USD
Book Value 0.20 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM -31 402 000 USD
Earnings per share -1.28 USD
Diluted Eps TTM -1.28 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CKPT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 18.52
Enterprise Value Revenue 8 235.69
Price Sales TTM 9 041.59
Enterprise Value EBITDA -0.54
Price Book MRQ 22.75

Technical Indicators CKPT

For 52 Weeks

2.06 USD 4.50 USD
50 Day MA 4.10 USD
Shares Short Prior Month 3 796 256
200 Day MA 3.39 USD
Short Ratio 3.18
Shares Short 2 956 398
Short Percent 3.68 %